BioNexus Gene Price To Earning vs. Return On Asset
| BGLC Stock | USD 0.29 0.01 3.33% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.13 | 0.1361 |
|
|
For BioNexus Gene profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BioNexus Gene to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well BioNexus Gene Lab utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BioNexus Gene's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of BioNexus Gene Lab over time as well as its relative position and ranking within its peers.
BioNexus |
Is Specialty Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNexus Gene. If investors know BioNexus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNexus Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (0.06) | Revenue Per Share 0.526 | Quarterly Revenue Growth (0.23) | Return On Assets (0.10) |
The market value of BioNexus Gene Lab is measured differently than its book value, which is the value of BioNexus that is recorded on the company's balance sheet. Investors also form their own opinion of BioNexus Gene's value that differs from its market value or its book value, called intrinsic value, which is BioNexus Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNexus Gene's market value can be influenced by many factors that don't directly affect BioNexus Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNexus Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNexus Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNexus Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
BioNexus Gene Lab Return On Asset vs. Price To Earning Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining BioNexus Gene's current stock value. Our valuation model uses many indicators to compare BioNexus Gene value to that of its competitors to determine the firm's financial worth. BioNexus Gene Lab is rated second in price to earning category among its peers. It is rated fourth in return on asset category among its peers . As of November 22, 2024, Return On Assets is expected to decline to -0.24. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BioNexus Gene's earnings, one of the primary drivers of an investment's value.BioNexus Return On Asset vs. Price To Earning
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
BioNexus Gene |
| = | 350.00 X |
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
BioNexus Gene |
| = | -0.1 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
BioNexus Return On Asset Comparison
BioNexus Gene is currently under evaluation in return on asset category among its peers.
BioNexus Gene Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in BioNexus Gene, profitability is also one of the essential criteria for including it into their portfolios because, without profit, BioNexus Gene will eventually generate negative long term returns. The profitability progress is the general direction of BioNexus Gene's change in net profit over the period of time. It can combine multiple indicators of BioNexus Gene, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -677.3 K | -643.4 K | |
| Net Income Applicable To Common Shares | 864.3 K | 907.5 K | |
| Income Tax Expense | 21.5 K | 20.4 K | |
| Operating Income | -2.6 M | -2.5 M | |
| Net Loss | -3.1 M | -2.9 M | |
| Income Before Tax | -2.6 M | -2.5 M | |
| Total Other Income Expense Net | -13.9 K | -13.2 K | |
| Net Loss | -2.6 M | -2.5 M | |
| Net Interest Income | -14.5 K | -15.2 K | |
| Non Operating Income Net Other | -210.6 K | -200 K | |
| Change To Netincome | 3.4 K | 3.6 K | |
| Net Loss | (0.17) | (0.16) | |
| Income Quality | 0.50 | 0.52 | |
| Net Income Per E B T | 1.01 | 0.70 |
BioNexus Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on BioNexus Gene. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of BioNexus Gene position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the BioNexus Gene's important profitability drivers and their relationship over time.
Use BioNexus Gene in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioNexus Gene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioNexus Gene will appreciate offsetting losses from the drop in the long position's value.BioNexus Gene Pair Trading
BioNexus Gene Lab Pair Trading Analysis
The ability to find closely correlated positions to BioNexus Gene could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioNexus Gene when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioNexus Gene - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioNexus Gene Lab to buy it.
The correlation of BioNexus Gene is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioNexus Gene moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioNexus Gene Lab moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioNexus Gene can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your BioNexus Gene position
In addition to having BioNexus Gene in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Insurance Thematic Idea Now
Insurance
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Insurance theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Insurance Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
To fully project BioNexus Gene's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of BioNexus Gene Lab at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include BioNexus Gene's income statement, its balance sheet, and the statement of cash flows.